tbuckley/cabot-search huggingface dataset:
Association of the Duration of Ideal Cardiovascular Health Through Adulthood With Cardiometabolic Outcomes and Mortality in the Framingham Offspring Study
Authors: Laura Corlin, Meghan I. Short, Ramachandran S. Vasan, Vanessa Xanthakis
Journal: JAMA Cardiology (2020)

The American Heart Association ideal cardiovascular health (CVH) score is associated with the risk of cardiovascular disease (CVD) and mortality. However, it is unclear whether the number of years spent in ideal CVH is associated with morbidity or with mortality.To evaluate whether living longer with a higher CVH score in midlife is associated with lower risk of hypertension, diabetes, chronic kidney disease, CVD and its subtypes (coronary heart disease, stroke, congestive heart failure, and peripheral artery disease), or all-cause mortality in later life.This prospective cohort study used data from 1445 participants from 1991 to 2015 who participated in the community-based Framingham Heart Study Offspring investigation conducted in Massachusetts. The CVH scores of participants were assessed at examination cycles 5, 6, and 7 (1991-1995; 1995-1998; and 1998-2001, respectively). Individuals were excluded from analyses of the association between duration of CVH score and outcomes if they had the outcome of interest at the seventh examination. The median follow-up was approximately 16 years. Data were analyzed from April 2018 to October 2019. The CVH score categories were poor for scores 0 to 7, intermediate for scores 8 to 11, and ideal for scores 12 to 14. A composite score was derived based on smoking status, diet, physical activity, resting blood pressure levels, body mass index, fasting blood glucose levels, and total serum cholesterol levels.Number of events and number at risk for each main outcome, including incident hypertension, diabetes, chronic kidney disease, CVD, and all-cause mortality, after the seventh examination.Of 1445 eligible participants, the mean (SD) age was 60 (9) years, and 751 (52%) were women. Number of events/number at risk for each main outcome after the seventh examination were 348/795 for incident hypertension, 104/1304 for diabetes, 198/918 for chronic kidney disease, 210/1285 for CVD, and 300/1445 for all-cause mortality. At the seventh examination, participants mostly had poor (568 [39%]) or intermediate (782 [54%]) CVH scores. For each antecedent (before examination cycle 7) 5-year duration that participants had intermediate or ideal CVH, they were less likely to develop adverse outcomes (hazards ratios of 0.67 [95% CI, 0.56-0.80] for incident hypertension, 0.73 [95% CI, 0.57-0.93] for diabetes, 0.75 [95% CI, 0.63-0.89] for chronic kidney disease, 0.73 [95% CI, 0.63-0.85] for CVD, and 0.86 [95% CI, 0.76-0.97] for all-cause mortality) relative to living the same amount of time in poor CVH (referent group). No effect modification was observed by age or by sex.These results suggest that more time spent in better CVH in midlife may have salutary cardiometabolic benefits and may be associated with lower mortality later in life.
EFFECTS OF RIVAROXABAN ON URINARY ALBUMIN EXCRETION IN PATIENTS WITH ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE: A RANDOMIZED TRIAL (X-NOAC)
Authors: Atsushi Tanaka, Makoto Suzuki, Kazuo Matsunaga, Isao Taguchi, Shiro Nakahara, Koichi Node
Journal: Journal of the American College of Cardiology (2020)
IL‐1β and IL‐17A are involved in IVIG resistance through activation of C/EBPβ and δ in a coronary artery model of Kawasaki disease
Authors: Takashi Inoue, Masaki Miyashita, Shokei Murakami, Arisa Igarashi, Kenichiro Motomura, Jun Abe, Kenji Matsumoto, Akio Matsuda
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis
Authors: Aileen G. Rowan, Richard Dillon, Aviva Witkover, Anat Melamed, Maria-Antonietta Demontis, Nicolas A. Gillet, Liew Jun Mun, Charles R. M. Bangham, Lucy B. Cook, Paul A. Fields, Graham P. Taylor
Journal: Blood (2020)
Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis
Authors: Shi-Ting Li, De Huang, Shengqi Shen, Yongping Cai, Songge Xing, Gongwei Wu, Zetan Jiang, Yijie Hao, Mengqiu Yuan, Nana Wang, Lianbang Zhu, Ronghui Yan, Dongdong Yang, Lin Wang, Zhaoji Liu, Xin Hu, Rongbin Zhou, Kun Qu, Ailing Li, Xiaotao Duan, Huafeng Zhang, Ping Gao
Journal: Nature Metabolism (2020)
INDEXED GLOBAL LONGITUDINAL STRAIN AS A PROGNOSTIC MARKER OF REVERSE LEFT ATRIAL REMODELING POST SUCCESSFUL MITRAL VALVE REPAIR IN DEGENERATIVE MITRAL REGURGITATION
Authors: Julia Grapsa, Santhi Adigopula, Shahna Suhail, Rawan Y. Elhenawy, Mohammed Khalil, Emin Murat Tuzcu, Tomislav Mihaljevic, Rakesh Suri
Journal: Journal of the American College of Cardiology (2020)
CRYPTOCOCCUS NEOFORMANS AUTOMATED IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (AICD) ENDOCARDITIS: A CHALLENGING CASE OF A RARE FUNGAL ENDOCARDITIS
Authors: Ahmed Altibi, Saleha Asghar, Lama Al Jebbawi, Ayman Battisha, Vivek Kak
Journal: Journal of the American College of Cardiology (2020)
ACUTE MYOCARDIAL INFARCTION COMPLICATED BY ATRIAL FIBRILLATION IS ASSOCIATED WITH INCREASED MORTALITY AND LENGTH OF STAY: A NEW YORK STATE INPATIENT DATA ANALYSIS
Authors: Xuming Dai, Christina Schweikert, Wenchen K. Wu, Rami Alsaber, Nikhil Yadav, David Slotwiner, Phyllis August
Journal: Journal of the American College of Cardiology (2020)
WHEN IS A BENIGN CARDIAC TUMOR NOT SO BENIGN? A CASE OF VENTRICULAR TACHYCARDIA CAUSED BY A CARDIAC HAMARTOMA
Authors: Zekun Feng, Daniel Philipson, Jamar P. Uzzell, Ashley Stein-Merlob, Eric H. Yang, Holly Middlekauff, Ryan P. Lau, Gregory A. Fishbein, Jason Bradfield, Olujimi Adeoluwa Ajijola
Journal: Journal of the American College of Cardiology (2020)
EFFECTS OF FEBUXOSTAT ON CAROTID INTIMA-MEDIA THICKNESS IN ASYMPTOMATIC HYPERURICEMIA: A RANDOMIZED CLINICAL TRIAL (PRIZE)
Authors: Atsushi Tanaka, Isao Taguchi, Nobukazu Ishizaka, Hirofumi Tomiyama, Masataka Sata, Shigeru Toyoda, Koji Maemura, Yukihito Higashi, Toyoaki Murohara, Koichi Node
Journal: Journal of the American College of Cardiology (2020)
GLOBAL LEFT VENTRICULAR MYOCARDIAL WORK EFFICIENCY AND LONG-TERM PROGNOSIS IN PATIENTS AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Rodolfo de Paula Lustosa, Pieter van der Bijl, Mohammed El Mahdiui, Jose Manuel Montero Cabezas, Marina V. Kostyukevich, Juhani M. Knuuti, Nina Ajmone Marsan, Jeroen Bax, Victoria Delgado
Journal: Journal of the American College of Cardiology (2020)
Another claim for cognitive history
Authors: Henry M. Cowles, Jamie Kreiner
Journal: Behavioral and Brain Sciences (2020)

Abstract History can help refine the resource-rational model by uncovering how cultural and cognitive forces act together to shape decision-making. Specifically, history reveals how the meanings of key terms like “problem” and “solution” shift over time. Studying choices in their cultural contexts illuminates how changing perceptions of the decision-making process affect how choices are made on the ground.
A new method of constructing CD20/CD22 bispecfic antibody fusion proteins with improved direct lymphoma cytotoxicity compared to rituximab
Authors: C. Chang, M. Losman, M. Loo, Z. Qu, E. A. Rossi, D. M. Goldenberg
Journal: Journal of Clinical Oncology (2006)

2536 Background: Anti-CD20 and anti-CD22 monoclonal antibodies (MAbs) have been shown to have antitumor activity in non-Hodgkin’s lymphoma (NHL) patients. Since preclinical and clinical trials also suggested that combining CD20 and CD22 MAbs, which have different mechanisms of action, could improve antitumor activity without a commensurate increase in toxicity, we hypothesized that a therapeutic advantage may be achieved with bispecific MAbs that bind simultaneously to both CD20 and CD22. Methods: A new platform technology, termed the Dock and Lock method (DNL), was successfully applied to produce a trivalent bispecific antibody, named TF3, which comprises two recombinant Fab fragments of hA20 (humanized anti-CD20 MAb; IMMU-106) stably tethered to one recombinant Fab fragment of epratuzumab (humanized anti-CD22 MAb; IMMU-103) via the specific interaction between a dimerization-and-docking domain and an anchoring domain appended to hA20 and epratuzumab, respectively. The cytotoxicity of TF3 was evaluated by cell-based assays using NHL cell lines. Results: TF3 is stable in both human and mouse sera andexhibitsthe samebinding affinity as hA20 IgG or epratuzumab Fab by competitive ELISA. With a 3-day MTT assay, TF3 at 10 nM inhibited 50% and 60% growth of Daudi and Ramos cells, respectively. Further, the observed anti-proliferative activity increased synergistically to &gt;90% in the presence of anti-IgM (0.1 μg/mL). Results from a cell counting assay also demonstrated the ability of TF3 at 1 μM to completely inhibit the growth of Daudi and the potency of TF3 at 1 nM was comparable to that of rituximab at 1 μM under the same experimental conditions, reflecting a 1000-fold enhancement. Conclusions: These findings, to be extended by ongoing in vivo studies, suggest that the new DNL platform technology for making bispecific antibody fusion proteins provided a CD20/CD22 binding protein that is significantly more potent than rituximab in an in vitro NHL direct cytotoxicity assay. [Table: see text]
PREDICTORS OF CLINICALLY SIGNIFICANT ATRIAL FIBRILLATION IN THE NHLBI HYPERTROPHIC CARDIOMYOPATHY REGISTRY (HCMR)
Authors: Christopher Kramer, John P. DiMarco, Paul Kolm, Carolyn Ho, Raymond Y. Kwong, Milind Y. Desai, Patrice Desvigne-Nickens, Sarahfaye Dolman, Evan Appelbaum, Matthias Friedrich, Nancy Geller, Michael Jerosch-Herold, Dong-Yun Kim, Martin Maron, Jeanette Schulz-Menger, Stefan Piechnik, Cheng Zhang, Hugh Watkins, William S. Weintraub, Stefan Neubauer
Journal: Journal of the American College of Cardiology (2020)
The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.
Authors: Suayib Yalcin, Neyran Kertmen, Deniz Yuce, Ferah Yildiz, Erhan Hamaloglu
Journal: Journal of Clinical Oncology (2013)

e15168 Background: Postoperative prognosis for ampullary carcinoma (AC) is superior to that of pancreatic cancer (PC), the former exhibiting higher complete surgical resection, lower recurrence and longer survival rates (1). Despite all the major recent advances in surgery, chemotherapy (CT) and RT, PC is still one of the most lethal malignancies, overall survival (OS) rates being as low as 5% at 5 years (2). This study was intended to evaluate survival in patients with resected periampullary cancer treated with adjuvant Gemcitabine (Gem) and cisplatin (Cis) with or without delayed RT (with Gem). Methods: This retrospective study involved 91 patients diagnosed and treated with periampullary cancer. Patients with adenocarcinoma of periampullary region with gross total tumor resection and lymph node dissection (R0 and R1 resections only) were included. Of 59 patients with PC, 38 received Gem and Cis for 3 cycles (3 months) before CRT. When delivered after Gem /RT, Gem and Cis were usually given for another 1-3 cycles. Twenty-seven patients received Gem and Cis alone over 6 cycles. Of 32 patients with non-pancreatic periampullary 23 received CT+CRT and 9 patients received CT alone. Results: Patients with non-pancreatic periampullary cancer had better OS (p:0.017) and disease free survival (DFS) ( p&lt;0.001 ) compared to patients with PC. Median OS of patients with PC was 21 months. Both OS and DFS were superior in the RT arm compared to nonRT arm (p: 0.043 and p &lt;0.001). In non-pancreatic periampullary cancer patients OS was 31 months in RT group and 51 months in non-RT group (p: 0.709). DFS was 29 months and 49.8 months respectively, p:0.504). Conclusions: The prognosis of PC was worse than non–pancreatic periampullary tumor. In PC adjuvant delayed RT improved patient outcome. Although OS and DFS were better in patients receiving CT alone, the difference was not statistically significant in non–pancreatic periampullary tumors.
5P Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
Authors: P. Tarantino, M. Minotti, P. Pricolo, G. Signorelli, A. Marra, C. Criscitiello, M. Locatelli, C. Belli, M. Bellomi, G. Curigliano
Journal: Annals of Oncology (2020)
African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.
Authors: Mitchell Bassett, Michael Abern, Lionel Lloyds Banez, Michael Ferrandino, Cary N. Robertson, Brant Allen Inman, Thomas Polascik, Stephen J. Freedland, Philip John Walther, Judd W. Moul
Journal: Journal of Clinical Oncology (2012)

4670 Background: As concerns mount regarding overtreatment and over-diagnosis of prostate cancer (CaP), active surveillance (AS) is increasingly utilized in low risk patients. While African-American (AA) race is associated with adverse outcomes after prostatectomy, its effect on patients managed with AS is not known. Methods: A retrospective review identified 222 patients managed with AS at the Duke Prostate Center from January 2005 to September 2011. All men had CaP diagnosed on biopsy performed at our center, and elected AS over treatment. Failure was defined as progression to treatment. In men who failed AS, the reasons for failure, follow-up PSA and biopsy characteristics were analyzed. The primary outcome - time from diagnosis to failure of AS for a reason other than patient choice - was analyzed with univariable and multivariable Cox proportional hazards models. Results: In our AS cohort, 73% are Caucasian and 23% AA. Median follow-up is 25.4 months. Age, household income, BMI, PSA, clinical stage, family history, prostate volume, number of cores with cancer, and Gleason grade on initial biopsy did not differ by race. The number of biopsies and PSA tests performed on AS did not differ by race. A higher proportion of AA men tended to fail from biopsy progression (72.7% vs. 63.8%) while a lower proportion failed by choice (9.1% vs. 14.9%) compared to Caucasians (p = 0.114). AA men had a significantly shorter time to failure (HR 1.74, p = 0.045) compared to Caucasians. There was a trend toward increased Gleason grade 8 or higher cancer on follow-up biopsy in AA compared to Caucasian men (10% vs. 2.5%, p = 0.08). AA race remained a predictor (HR 1.76, p = 0.058) of failure on multivariable analysis, as did initial PSA (HR 1.90, p = 0.031) and number of cores with cancer on initial biopsy (HR 1.29, p = 0.013). Conclusions: AA race was associated with higher risk for failure of AS. There was a trend toward AA men failing due to biopsy progression and with higher grade cancer. Additional follow-up is necessary to determine how this affects the long term outcomes of these men.
COST EFFECTIVE HEART FAILURE MANAGEMENT PROGRAM IN A SAFETY NET HOSPITAL: IS IT FEASIBLE?
Authors: Anekwe E. Onwuanyi, Michael Knauss, Diane Wirth, Faith Works-Fleming, Andrea Cafarelli, Bick Amy, Brandi Quinn, Modele Ogunniyi, Eva Gourrier, Tara Shropshire, Jeff Herald
Journal: Journal of the American College of Cardiology (2020)
Preoperative thrombocytosis as a predictor of unfavorable survival in resectable non-small cell lung cancer.
Authors: Jiwen Wang, Min Luo, Hanmo Wu, Liming Sheng, Dan Su, Weimin Mao
Journal: Journal of Clinical Oncology (2013)

e18531 Background: Activated platelet is thought to promote cancer cells growth and metastasis, playing an important role in progression of cancer. However, the association between platelet counts and prognosis of patient with non small cell lung cancer (NSCLC) had not been fully elucidated. The aim of this study is to investigate the prognostic value of platelet counts in resectable NSCLC. Methods: A total of 636 primary NSCLC patients who had curatively resected surgery in Zhejiang Cancer Hospital from November 2006 to January 2011 were retrospectively analyzed. Preoperative platelet counts and clinicopathological factors were collected from the medical record database. Patients were followed up for disease progression free survival (PDS) and overall survival (OS) until January 20, 2013. The association between platelet counts and patients’ outcome were evaluated. Results: In all patients, 13.8% (88/636) had increased platelet count (&gt;300 × 10 9 /L), referred to as thrombocytosis. The proportion of thrombocytosis was significantly higher in male, squamous-cell carcinoma and stage III than that in female, other histological types and early stage NSCLC. Moreover, thrombocytosis was associated with significantly shortened survival. Multivariate Cox analysis showed patient with thrombocytosis not only had a 1.66 time elevated risk for disease progression (95% CI, 1.14-2.41, p=0.009), but also had and a 1.47 time risk for death (95% CI, 1.04-2.08, P=0.029), compared with that in those having normal platelet count. More interestingly, the risk for replase was increased to 3.19 times (95% CI, 1.41-7.23, p=0.006) in stage I NSCLC with thrombocytosis than that in patients with normal platelet count after stratified analysis by stage. Conclusions: Preoperative platelet count is an independent prognostic predictor in operable NSCLC, especially in early stage I NSCLC. Platelet count may serve as a useful indicator and potential target for personalized treatment with antiplatelet reagent.
Phase II study of capecitabine (X) plus reirradiation in patients (pts) with recurrent squamous cell carcinoma of the head and neck (SCCHN)
Authors: G. Kornek, L. Vormittag, M. Burian, D. Radonjic, E. Selzer
Journal: Journal of Clinical Oncology (2006)

15504 Background: X has shown substantial activity in SCCHN [Pivot et al. 2004] and is replacing 5-FU as the backbone of chemotherapy in a wide range of solid tumors, particularly colorectal cancer. In addition, X has a unique survival benefit in breast cancer. There is substantial data to support using X in chemoradiation [Dunst et al. 2004]. We evaluated the therapeutic impact and safety profile of X plus reirradiation in SCCHN. Methods: Pts with locally advanced unresectable SCCHN who had prior radiotherapy (RT, with or without chemotherapy) received X 450 mg/m 2 twice daily, 7 days a week. RT was delivered as a standard fractionated regimen (2 Gy/day, 5 fractions/week) up to a total dose of 50–70 Gy. The cumulative (life-time) dose within overlapping fields was not to exceed 120–130 Gy. Results: Currently, 20 male pts have completed treatment. Baseline characteristics were: median age 57 (42–72), ECOG PS 0/1 5/15. Six pts had previous chemoradiation followed by radical resection; 4 had surgery and postoperative RT; 10 had concomitant chemoradiation (accelerated and hyperfractionated). Twelve pts experienced locoregional recurrences, 4 developed secondary primaries, and 4 had a regional lymph node relapse. The median time since prior radiation therapy was 16 (8–244) months. Efficacy (as evaluated by WHO criteria): 7 pts (35%) had a complete (2) or partial (5) response; stable disease was observed in 11 pts, and tumor progression immediately after therapy was observed in 2 pts. Median duration of local control and median survival will be presented at the meeting. The most frequently observed toxicity was mucositis, which was grade 3 in only 2 pts; grade 1 or 2 skin reaction was seen in 9 pts. There was no evidence of systemic toxicity or myelosuppression, probably due to the very low dose of X. RT was completed without delay in all pts, and X was interrupted prematurely in 2 pts due to grade 3 mucositis. Conclusions: Our preliminary data suggest that X chemoradiation is a well-tolerated and effective treatment modality for previously irradiated pts with SCCHN. Based on available data, a higher dose of X should be feasible and potentially more effective. Earlier use of X in SCCHN could also be evaluated. [Table: see text]
TRANSIENT LOAD DEPENDENT SEVERE AORTIC REGURGITATION IN A PATIENT WITH STENTLESS AORTIC VALVE REPLACEMENT
Authors: Saman Setareh-Shenas, Vaani Garg, Asad Mohammad, Pankaj Khullar, Eyal Herzog, Alan Rozanski, Edgar Argulian
Journal: Journal of the American College of Cardiology (2020)
PREDICTORS OF BASELINE HISTORY OF ATRIAL FIBRILLATION AT THE TIME OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANT AND ASSOCIATION OF ATRIAL FIBRILLATION WITH SUBSEQUENT CLINICAL OUTCOMES
Authors: Shaun Giancaterino, Marin Nishimura, Ulrika Birgersdotter-Green, Kurt S. Hoffmayer, Frederick T. Han, Farshad Raissi, Gordon Ho, David Krummen, Gregory Feld, Jonathan Chong Hsu
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF OVERWEIGHT ON THE SAFETY AND EFFICACY OF A PLATELET FUNCTION TEST BASED DE-ESCALATION STRATEGY OF PRASUGREL VERSUS CLOPIDOGREL AMONG ACUTE CORONARY SYNDROME PATIENTS AFTER PCI
Authors: András Komócsi, Daniel Aradi, Bela Merkely, Martin Hadamitzky, Steffen Massberg, Konstantinos Rizas, Ralph Hein-Rothweiler, Lisa Gross, Dietmar Trenk, Dirk Sibbing
Journal: Journal of the American College of Cardiology (2020)
LEVERAGING THE LAW OF LAPLACE: SUCCESSFUL TRANSCAVAL ACCESS THROUGH AN ABDOMINAL AORTIC ANEURYSM FOR IMPELLA ASSISTED DISTAL LEFT MAIN INTERVENTION FOLLOWED BY SELF EXPANDING TAVR VALVE
Authors: Neel Parikh, Jatinder Banipal, Matthew Cauchi, Jason Foerst
Journal: Journal of the American College of Cardiology (2020)